Literature DB >> 17601631

Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

Ryotaro Morinaga1, Isamu Okamoto, Kazuyuki Furuta, Yukiko Kawano, Masaru Sekijima, Kensaku Dote, Takao Satou, Kazuto Nishio, Masahiro Fukuoka, Kazuhiko Nakagawa.   

Abstract

We report a case of small cell lung cancer (SCLC) developing after prolonged treatment (more than 2 years) for primary adenocarcinoma of the lung, and we show that both the SCLC and non-small cell lung cancer (NSCLC) tissues obtained from the same site share the same deletion in exon 19 of EGFR. This case suggests that the activating EGFR mutations may confer the pathogenesis of a subset of SCLC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17601631     DOI: 10.1016/j.lungcan.2007.05.014

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  53 in total

1.  Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study.

Authors:  S Vatrano; L Righi; T Vavalá; I Rapa; M Busso; S Izzo; S Cappia; A Veltri; M Papotti; G V Scagliotti; S Novello
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

Review 2.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors:  Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

Review 3.  Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration.

Authors:  Alessandro Tuzi; Elena Bolzacchini; Matteo B Suter; Alice Giaquinto; Antonio Passaro; Stefania Gobba; Ilaria Vallini; Graziella Pinotti
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

4.  Contrast-enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early-phase non-small cell lung cancer.

Authors:  Ninglu Yuan; Xiaohe Zhang; Yonghui Cao; Xiaojie Jiang; Si Zhao; Yingying Feng; Yimeng Fan; Zhitao Lu; Hongmei Gao
Journal:  Exp Ther Med       Date:  2017-09-19       Impact factor: 2.447

Review 5.  New Approaches to SCLC Therapy: From the Laboratory to the Clinic.

Authors:  John T Poirier; Julie George; Taofeek K Owonikoko; Anton Berns; Elisabeth Brambilla; Lauren A Byers; David Carbone; Huanhuan J Chen; Camilla L Christensen; Caroline Dive; Anna F Farago; Ramaswamy Govindan; Christine Hann; Matthew D Hellmann; Leora Horn; Jane E Johnson; Young S Ju; Sumin Kang; Mark Krasnow; James Lee; Se-Hoon Lee; Jonathan Lehman; Benjamin Lok; Christine Lovly; David MacPherson; David McFadden; John Minna; Matthew Oser; Keunchil Park; Kwon-Sik Park; Yves Pommier; Vito Quaranta; Neal Ready; Julien Sage; Giorgio Scagliotti; Martin L Sos; Kate D Sutherland; William D Travis; Christopher R Vakoc; Sarah J Wait; Ignacio Wistuba; Kwok Kin Wong; Hua Zhang; Jillian Daigneault; Jacinta Wiens; Charles M Rudin; Trudy G Oliver
Journal:  J Thorac Oncol       Date:  2020-02-01       Impact factor: 15.609

6.  Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma.

Authors:  Greta Alì; Rossella Bruno; Mirella Giordano; Irene Prediletto; Letizia Marconi; Simonetta Zupo; Franco Fedeli; Alessandro Ribechini; Antonio Chella; Gabriella Fontanini
Journal:  Oncol Lett       Date:  2016-09-26       Impact factor: 2.967

Review 7.  EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Authors:  Yuxin Lin; Xian Wang; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 8.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

Review 9.  Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

Authors:  Rita Dorantes-Heredia; José Manuel Ruiz-Morales; Fernando Cano-García
Journal:  Transl Lung Cancer Res       Date:  2016-08

Review 10.  Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

Authors:  Justin F Gainor; Alice T Shaw
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.